Introduction {#s1}
============

Obesity is a growing problem worldwide ([@bib23]; [@bib41]) and thus an urgent need exists to identify molecular processes and signaling pathways that may serve as novel therapeutic targets to hinder obesity-induced pathologies. Although the underlying causes of obesity-related complications are multifactorial, the dysfunction of adipose tissue plays a central role in the development of peripheral tissue metabolic disturbances, ultimately reflecting systemically in dyslipidemia, insulin resistance and hyperglycemia ([@bib23]; [@bib13]).

Capillary endothelial cells (EC) are well-known regulators of tissue adaptation to pathologic challenges through their prominent role in blood vessel formation and remodeling. During expansion of visceral adipose tissue, impaired vascular remodeling promotes hypoxia, inflammation, and fibrosis ([@bib6]; [@bib13]). Conversely, forced stimulation of vascular growth in adipose tissue of obese rodents improves adipose tissue function ([@bib37]; [@bib28]; [@bib33]), counteracting obesity-related metabolic disorders ([@bib38]; [@bib33]). These findings indicate that the remodeling capacity of microvascular ECs during obesity is vital not only for the adipose tissue function but also for the development of systemic metabolic disturbances. However, surprisingly little is understood about the signaling pathways that limit the angiogenic response of EC in obesity.

Forkhead Box O1 (FoxO1) signaling is essential to the homeostasis of EC and restricts vascular growth ([@bib43]). In addition to the control of angiogenesis-related genes ([@bib27]; [@bib26]; [@bib22]; [@bib29]; [@bib43]), FoxO1 is a gatekeeper of EC metabolism; its overexpression reduces the metabolic rate of EC and enforces a state of endothelial quiescence ([@bib43]). Thus, this transcription factor is one of the major regulators of angiogenic capacity, since the switch from a quiescent to an angiogenic phenotype requires a coordinated increase in EC metabolic activity to meet the higher demand for energy and biomass production associated with proliferation and migration ([@bib8]; [@bib32]; [@bib20]).

Compelling observational evidence indicates that endothelial FoxO1 dysregulation coincides with obesity-associated metabolic disturbances. For instance, FoxO1 protein levels were elevated in capillaries from skeletal muscle of mice fed a high-fat diet ([@bib25]) and the activity of endothelial FoxO1 correlated with adipose insulin resistance of obese subjects ([@bib19]). Additionally, in vitro conditions that mimic hyperglycemia and insulin resistance increase FoxO1 protein and activity in EC ([@bib39]; [@bib25]). Nevertheless, to our knowledge, the contribution of FoxO1 signaling to vascular remodeling during obesity has not been addressed experimentally. To date, only a few reports have assessed the relevance of endothelial FoxO proteins in diet-induced disorders, but none have examined the influence on adipose tissue. Moreover, those studies employed simultaneous EC-specific depletion of multiple FoxOs (FoxO1, FoxO3, and FoxO4) and transgenic lines in which gene targeting was not exclusive to EC ([@bib39]; [@bib42]; [@bib25]), preventing discrimination of the specific functions of endothelial FoxO1. Notably, it has been shown that in vitro conditions associated with FoxO1 dysregulation can also compromise EC metabolism ([@bib44]; [@bib11]; [@bib18]). Although this suggests that the interplay between endothelial FoxO1 levels and EC metabolic activity may be critically implicated in limiting vascular remodeling in obesity, this concept demands validation.

The converging roles of FoxO1 in the angiogenic phenotype and the metabolism of quiescent EC led us to hypothesize that FoxO1 is a critical nodal point in determining the response of capillary EC to obesity. Consequently, we postulated that targeted endothelial-specific depletion of FoxO1 would provoke capillary growth, preventing obesity-driven adipose tissue dysfunction, and provide a valuable tool to unmask the role of the microvascular endothelium metabolism in the pathophysiology of obesity.

Results {#s2}
=======

Mice with EC-FoxO1 depletion exhibit greater vascular density in visceral adipose tissue {#s2-1}
----------------------------------------------------------------------------------------

To assess the involvement of EC-FoxO1 in the control of vascular growth in the adipose tissue of adult mice, we utilized a mouse model of EC-selective depletion of FoxO1 expression (referred to 'EC-FoxO1 KD' mice hereafter) through inactivation of the *Foxo1* gene specifically in EC. *Foxo1* floxed (*Foxo1^f/f^*) mice were crossbred with *Pdgfb*-iCreERT2 mice that express tamoxifen-activated Cre recombinase in EC and Cre-mediated recombination of *Foxo1* was induced in adult mice. Littermate mice homozygous for the floxed *Foxo1* allele but not expressing Cre recombinase were used as controls. After tamoxifen injection, *Foxo1* recombination was observed within adipose and skeletal muscle but not within the liver, as endothelial *Pdgfb* expression is undetectable in this organ ([@bib16]). The endothelial cell specificity of the recombinase activity was confirmed in microvascular EC isolated from adipose tissue ([Figure 1A](#fig1){ref-type="fig"}). Consequently, *Foxo1* transcript level, as measured by qPCR, was decreased by 50% in microvascular EC of EC-FoxO1 KD mice relative to control littermates 8 weeks after the administration of tamoxifen, confirming effective and stable *Foxo1* depletion in these cells ([Figure 1B](#fig1){ref-type="fig"}). Of note, *Foxo3* mRNA expression was unaltered in microvascular EC ([Figure 1B](#fig1){ref-type="fig"}), demonstrating a lack of compensation by this FoxO family member in response to the depletion of *Foxo1*. Moreover, consistent with the previously described absence of *Pdgfb*-Cre activity within macrophages ([@bib5]), no significant changes in *Foxo1* mRNA levels were detected in CD16/CD32^+^ immune cells from white adipose tissue ([Figure 1C](#fig1){ref-type="fig"}), indicating that Cre-mediated recombination did not occur in these stromal cells. The depletion of EC-*Foxo1* in microvascular beds of EC-FoxO1 KD mice also was validated via assessment of FoxO1 protein levels by Western blotting. In agreement with the lower mRNA levels observed in microvascular ECs from adipose tissue, protein levels of FoxO1 were diminished by 70% in capillary fragments from skeletal muscle of EC-FoxO1 KD mice compared to control littermates 6 weeks after the administration of tamoxifen ([Figure 1D](#fig1){ref-type="fig"}). Together, these results not only imply that successful *Foxo1* depletion was constrained to the endothelial cell compartment, particularly microvascular beds, but also support the use of EC-FoxO1 KD mice as an appropriate model to assess the relevance of endothelial FoxO1 for vascular remodeling during adipose tissue expansion.

![Endothelial-specific depletion of *Foxo1* induced in adult male mice effectively reduces FoxO1 levels in skeletal muscle and adipose microvascular beds.\
(**A**) PCR of genomic DNA from multiple organs of control (Cre^-^; *Foxo1^f/f^*) and EC-FoxO1 KD mice using primers for the floxed and deleted (E1∆E3) alleles. (**B--C**) Gene expression analysis of microvascular EC and CD16/CD32^+^ cells isolated from white adipose tissue of Control (n = 6) and EC-FoxO1 KD (n = 3--5) mice. (**D**) Representative Western blot images and quantitative analysis of FoxO1 and β-actin levels in capillary fragments isolated from skeletal muscle (n = 3--4). Results are expressed relative to β-actin levels. Data in all panels are expressed as mean ± SEM; \*p \< 0.05, \*\*p \< 0.01, calculated with two-tailed unpaired *t*-test.](elife-39780-fig1){#fig1}

EC-FoxO1 KD mice maintained on a normal chow (NC) diet for 16 weeks exhibited no gross abnormalities and similar body weight gain compared to control counterparts (8.32 ± 1.3 *vs*. 7.75 ± 1.17 g, n = 6/group), but significantly increased mRNA levels of the EC marker *Pecam1* in eWAT ([Figure 2A](#fig2){ref-type="fig"}). When blood vessels were visualized by whole-mount staining with *G. simplicifolia* lectin, it was evident that the vascular density of visceral adipose tissue from EC-FoxO1 KD mice ([Figure 2B--C](#fig2){ref-type="fig"}) was significantly higher. EC-FoxO1 depletion did not alter the number of vessel branch points ([Figure 2D](#fig2){ref-type="fig"}). On the other hand, vessels in the adipose of EC-FoxO1 KD mice were significantly enlarged, showing increased vessel diameter, compared to control littermates ([Figure 2E](#fig2){ref-type="fig"}), which was consistent with the reported influence of EC-*Foxo1* depletion in vascular development in retinas ([@bib43]). No difference in the expression of *Pecam1* was detected in other assessed tissues, such as skeletal muscle and liver ([Figure 2A](#fig2){ref-type="fig"}).

![Greater vascular density in visceral adipose tissue of normal chow-fed EC-FoxO1 KD mice.\
(**A**) *Pecam1* mRNA levels in various tissues of Control and EC-FoxO1 KD mice after 16 weeks of normal chow (NC) diet (Control n = 6, EC-FoxO1 KD n = 5). (**B**) Representative confocal images of adipose tissue whole-mount staining with BODIPY 493/503 (green) and *G. simplicifolia* lectin (red) (×20 magnification; scale bar = 100 μm). (**C--E**) Lectin area (**C**), capillary branch density (**D**) and microvessel diameters (**E**) were quantified from confocal images (Control n = 5, EC-FoxO1 KD n = 6). Data in all panels are expressed as mean ± SEM; \*p \< 0.05, \*\*p \< 0.01, calculated with two-tailed unpaired *t*-test.](elife-39780-fig2){#fig2}

EC-FoxO1 depletion provokes greater microvascular remodeling under the stimulus of a high-fat diet {#s2-2}
--------------------------------------------------------------------------------------------------

To determine whether EC-FoxO1 depletion evokes vascular growth during adipose expansion in response to excess caloric consumption, we challenged mice with a prolonged high-fat diet (HF) and assessed tissue angiogenesis. Gene expression analysis indicated that EC-FoxO1 depletion resulted in higher *Pecam1* mRNA levels in multiple adipose tissue depots: eWAT, subcutaneous and brown adipose tissue (BAT, [Figure 3A](#fig3){ref-type="fig"}). In line therewith, transcript levels of other EC markers, von Willebrand factor (*Vwf*) and endothelial nitric oxide synthase (*Nos3*) were elevated in the eWAT of HF-fed EC-FoxO1 KD mice ([Figure 3B](#fig3){ref-type="fig"}). Whole-mount staining of adipose tissue revealed remarkable increases in vascular area and number of vessel branch points in the eWAT of HF-fed EC-FoxO1 KD ([Figure 3C--E](#fig3){ref-type="fig"}). Consistently, quantitative histological analysis showed that capillary number per adipocyte (capillary to adipocyte ratio) was significantly higher in eWAT of HF-fed EC-FoxO1 KD mice, further validating the greater microvascular content in eWAT of these mice compared to HF-fed control counterparts ([Figure 3F--G](#fig3){ref-type="fig"}). Furthermore, EC-FoxO1 depletion led to significant capillary enlargement in eWAT ([Figure 3H--I](#fig3){ref-type="fig"}). Of note, the increase of vessel diameter in HF-fed EC-FoxO1 KD mice was greater than observed in NC-fed EC-FoxO1 KD mice (1.8 *vs.* 1.3-fold increase), suggesting that the enlargement of capillaries promoted by EC-FoxO1 depletion is exacerbated by HF feeding.

![EC-*Foxo1* depletion strongly induces vascular growth within adipose tissue in response to HF diet.\
(**A**) *Pecam1* mRNA levels in different adipose tissue depots of Control and EC-FoxO1 KD mice after 16 weeks of high-fat (HF) diet (Control n = 5--7, EC-FoxO1 KD n = 7). (**B**) Gene expression analysis of eWAT of HF-fed Control and EC-FoxO1 KD mice (Control n = 7, EC-FoxO1 KD n = 6--7). (**C**) Representative confocal images of adipose tissue whole-mount staining with BODIPY 493/503 (green) and *G. simplicifolia* lectin (red) (C - scale bar = 100 μm). (**D,E and I**). Lectin area (**D**) and capillary branch density were quantified from these images (Control, n = 6; EC-FoxO1 KD, n = 5 or 6). (**F--G**) *G. simplicifolia* lectin (green) and Wheat germ aggluttinin (red) staining of paraffin-sectioned adipose tissue (F - scale bar = 100 μm) was used to assess capillary to adipocyte ratio (**G**). (**H**) Representative confocal images of adipose tissue whole-mount staining with Isolectin alone (greyscale; scale bar = 20 μm). (**I**) Microvessel diameters were quantified from confocal images (Control, n = 6; EC-FoxO1 KD, n = 6). Data in all panels are expressed as mean ± SEM; \*p \< 0.05, \*\*\*p \< 0.001, calculated with two-tailed unpaired *t*-test.](elife-39780-fig3){#fig3}

Subsequent gene expression analysis showed that EC-FoxO1 depletion did not change transcript levels of *Pecam1* in the liver (corresponding with the lack of Cre recombination in this organ) but did upregulate its expression in skeletal muscle, suggesting that under the stimulus of HF diet, EC-FoxO1 depletion also induces microvascular remodeling in this tissue ([Figure 4A](#fig4){ref-type="fig"}). Skeletal muscle of HF-fed EC-FoxO1 KD mice displayed a trend towards higher capillary:fiber ratio (p = 0.06) compared to control mice ([Figure 4B--C](#fig4){ref-type="fig"}). Transmission electron microscopy revealed increased capillary endothelial cross-sectional area and capillary lumen diameters in skeletal muscle of EC-FoxO1 KD mice, demonstrating a modest expansion of the size of individual capillaries ([Figure 4D--F](#fig4){ref-type="fig"}). Taken together, these data indicate that EC-FoxO1 depletion results in remarkable vascular growth in response to HF diet, which is particularly pronounced within visceral adipose tissue.

![EC-*Foxo1* depletion also favors microvascular expansion in skeletal muscle under HF diet feeding.\
(**A**) *Pecam1* mRNA levels in liver and skeletal of HF-fed Control (n = 5--6) and EC-FoxO1 KD (n = 6--7) mice. (**B**) Images of EDL muscle stained with Isolectin-FITC to identify capillaries (scale bar = 50 μm). (**C**) Capillary to fiber (C:F) ratios were calculated from 3 to 4 independent fields of view per mouse (Control n = 6, EC-FoxO1 KD n = 6). (**D**) Representative EM images of capillaries within skeletal muscle from HF-fed Control and EC-FoxO1 KD mice (×6.5k magnification; scale bar = 2 μm). (**E--F**) EC cross-sectional area (**E**) and capillary luminal diameter were quantified from EM images from n = 4 mice per group, with individual capillary measurements shown (**F**). Data in all panels are expressed as mean ± SEM; \*p \< 0.05, calculated with two-tailed unpaired *t*-test.](elife-39780-fig4){#fig4}

EC-FoxO1 KD mice exhibit a healthier adipose tissue expansion in response to HF diet {#s2-3}
------------------------------------------------------------------------------------

The vasculature is critical for maintenance of adipose tissue homeostasis during obesity-driven adipocyte enlargement. Thus, we inferred that the increased vascular density observed with EC-FoxO1 depletion may hinder adipose tissue expansion and dysfunction induced by high-fat diet. Although HF-fed EC-FoxO1 KD mice showed only a trend towards reduced body weight gain (p = 0.06), these mice displayed less fat accumulation, showing lower trunk fat content, smaller retroperitoneal (rWAT) and subcutaneous fat pads compared to control mice ([Figure 5A--C](#fig5){ref-type="fig"} and [Table 1](#table1){ref-type="table"}). The phenotype was not explained by changes in food consumption ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). HF-fed EC-FoxO1 KD mice also displayed lower fed levels of serum triglycerides and glycerol, and less hepatic lipid accumulation ([Figure 5---figure supplement 1B--D](#fig5s1){ref-type="fig"}), suggesting an improvement in the capacity to handle dietary nutrient excess in these mice. Moreover, histological analysis revealed that increased vascular growth in adipose tissue of HF-fed EC-FoxO1 KD mice was associated with smaller-sized and generally spherical adipocytes, whereas adipocytes from HF-fed control mice were large with irregular polygonal shapes ([Figure 5D--E](#fig5){ref-type="fig"}), which was previously related to cellular stress ([@bib14]). Of note, adipocytes from EC-FoxO1 KD mice retained a unilocular structure ([Figure 5D](#fig5){ref-type="fig"}) rather than the hallmark multilocular morphology of brown fat. Furthermore, no change in the mRNA levels of browning markers *Ucp1* and *Prdm16* ([Figure 5F](#fig5){ref-type="fig"}) was detected with EC-FoxO1 depletion. Correspondingly, we did not observe any difference in mitochondrial protein content of eWAT nor in ADP-stimulated respiration through either Complex I (pyruvate/malate, glutamate) or Complex II (succinate) ([Figure 5---figure supplement 2A--C](#fig5s2){ref-type="fig"}). Isoproterenol-stimulated phosphorylation of the hormone-sensitive lipase (HSL) was unaffected ([Figure 5---figure supplement 2D--E](#fig5s2){ref-type="fig"}), indicating that EC*-*FoxO1 depletion did not impact the adipose tissue sensitivity to lipolytic stimuli. In contrast, and consistent with an improved function, eWAT from HF-fed EC-FoxO1 KD mice displayed enhanced Akt phosphorylation in response to insulin ([Figure 5G--H](#fig5){ref-type="fig"}), which was accompanied by higher *Adiponectin* mRNA levels and concomitant lower *Leptin* expression ([Figure 5I](#fig5){ref-type="fig"}). Collectively, these findings demonstrate that depletion of EC-FoxO1 signaling exerts a protective effect against obesity-induced metabolic remodeling of adipose tissue without promoting a browning phenotype. Notably, the transcripts levels of *Vegfa* and *Apelin* were also higher in eWAT from HF-fed EC-FoxO1 KD mice ([Figure 5J](#fig5){ref-type="fig"}), providing evidence that the improvements in adipose phenotype include a more pro-angiogenic adipose tissue microenvironment.

![EC-FoxO1 KD mice exhibit a healthier adipose tissue expansion in response to HF diet.\
(**A**) Body weights during 16 weeks of HF feeding. (**B**) Summarized weight gain over the course of 0--14 weeks (Control n = 7, EC-FoxO1 KD n = 7). (**C**) Abdominal transverse micro-CT images of HF-fed Control (n = 5) and EC-FoxO1 KD (n = 6) mice (upper panel). Fat content (shown in white) was calculated as % of total trunk volume. (**D**) Representative hematoxylin and eosin-stained images of adipose tissue from the epididymal fat pad (scale bar = 100 μm). (**E**) Mean adipocyte cross-sectional area (Control n = 5 EC-FoxO1 KD n = 5). (**F**) mRNA for browning markers *Ucp1* and *Prdm16* relative to *Hprt1* (Control n = 7, EC-FoxO1 KD n = 7). (**G--H**) Representative Western blot images (**G**) and quantitative analysis (**H**) of pSer473-Akt and total Akt levels in eWAT after ex vivo incubation in the absence or presence of insulin. Results are expressed relative to total Akt levels (Control n = 4, EC-FoxO1 KD n = 7). (**I--J**) mRNA for adipokines (I, *Adipoq* and *Leptin*) and angiogenic markers (J, *Vegfa* and *Apln*) in eWAT relative to *Hprt1* (Control n = 6--7, EC-FoxO1 KD n = 5--7). Data in all panels are expressed as mean ± SEM; \*p \< 0.05, \*\*p \< 0.01, calculated with two-tailed unpaired *t*-test.](elife-39780-fig5){#fig5}
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###### Tissue weights of Control and EC-FoxO1 KD mice after 16 weeks of HF diet

                                   Control        EC-FoxO1 KD
  -------------------------- -- -- -------------- ------------------
  Body weight (g)                  44 ± 1.1       38 ± 2.2
  eWAT (g)                         1.8 ± 0.2      1.6 ± 0.6
  rWAT (mg)                        881.7 ± 86.1   579.8 ± 98.7^\*^
  Subcutaneous adipose (g)         2.1 ± 0.3      1.3 ± 0.2^\*^
  BAT (mg)                         189.2 ± 21.2   144.3 ± 14.8
  Liver (g)                        1.5 ± 0.1      1.2 ± 0.1^\*^
  Heart (mg)                       135 ± 4.2      126.6 ± 3.4
  Gastrocnemius (mg)               130.9 ± 4.3    115.5 ± 4.4^\*^
  Soleus (mg)                      8.3 ± 0.5      8.0 ± 0.5
  Tibialis anterior (mg)           44.5 ± 1.5     42.6 ± 1.4

eWAT: epididymal adipose tissue; rWAT: retroperitoneal adipose tissue; BAT: brown adipose tissue.

Data are expressed as mean ± SEM, n = 7 per group.

Significance was established using unpaired *t*-test.

^\*^*P* \< 0.05 *vs* Control group.

EC-FoxO1 depletion provokes a metabolic shift favoring glucose utilization in HF-fed mice {#s2-4}
-----------------------------------------------------------------------------------------

To better understand the metabolic consequences of EC-FoxO1 depletion, whole-body metabolic functions were monitored for 48 hr in a 2^nd^ cohort of HF-fed mice. Surprisingly, EC-FoxO1 KD mice exhibited reduced VO~2~ and increased RER during the dark cycle ([Figure 6A,C](#fig6){ref-type="fig"}) with equivalent CO~2~ production and activity levels compared to control mice ([Figure 6B,D](#fig6){ref-type="fig"}). These data unexpectedly indicated that EC-FoxO1 KD mice increased oxidation of carbohydrate relative to fatty acid as an energy substrate, suggesting that EC-FoxO1 depletion shifted whole-body energy homeostasis towards glucose oxidation. Consistent with these findings, HF-fed EC-FoxO1 KD mice displayed more rapid glucose clearance from the blood during glucose tolerance tests ([Figure 6E--F](#fig6){ref-type="fig"}). However, higher glucose tolerance was not associated with altered whole-body insulin sensitivity, based on insulin tolerance tests (ITT) ([Figure 6G--H](#fig6){ref-type="fig"}) or insulin-mediated Akt phosphorylation in the skeletal muscle ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Despite the effects on glucose metabolism observed in HF-fed EC-FoxO1 KD mice, no change in whole-body glucose metabolism was detected in NC-fed EC-FoxO1 KD mice compared to control counterparts ([Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}). Interestingly, fasting glycemia was significantly lower ([Figure 6I](#fig6){ref-type="fig"}) whereas serum lactate levels were elevated in HF-fed EC-FoxO1 KD mice compared to their littermates (10.9 ± 0.39 *vs*. 9.4 ± 0.55 mmol/L, respectively, p = 0.04, n = 7/group). These findings imply that altered whole-body glucose metabolism of EC-FoxO1 KD mice on a HF may be due to higher glucose turnover, leading us to postulate that increased glycolytic rates at the tissue level contribute to the metabolic phenotype of HF- EC-FoxO1 KD mice. To address this question, we first assessed the expression of main glycolytic genes, including the constitutive glucose transporter GLUT1 (*Slc2a1*), the rate-limiting enzymes hexokinase 2 (*Hk2*) and phosphofructokinase (*Pfkm*) and phosphofructokinase-2/fructose-2,6-bisphosphatase-3 (*Pfkfb3*). As anticipated, the mRNA levels of most glycolytic genes, with the exception of *Pfkfb3*, were upregulated in the eWAT from HF-fed EC-FoxO1 KD mice compared to control mice, ([Figure 6J](#fig6){ref-type="fig"}). Furthermore, mRNA levels of the lactate transporter, monocarboxylate transporter 5, *Slc16a4*, were also increased in eWAT of HF-fed EC-FoxO1 KD mice ([Figure 6K](#fig6){ref-type="fig"}), consistent with an increased glycolytic flux of glucose to lactate in the adipose tissue of these mice.

![EC-*Foxo1* depletion improves glucose homeostasis in HF-fed mice.\
(**A--D**) O~2~ consumption (**A**), CO~2~ production (**B**), Respiratory exchange ratio - RER (**C**) and daily activity (**D**) were measured during indirect calorimetry tests using a comprehensive laboratory animal monitoring system (CLAMS, Control n = 5, EC-FoxO1 KD n = 6). (**E**) Glucose tolerance of HF-fed Control and EC-FoxO1 KD mice was examined by intraperitoneal glucose tolerance test after 15 weeks of HF diet and 16 hr fasting. (**F**) Area under the curve (AUC, Control n = 7, EC-FoxO1 KD n = 7). (**G**) Insulin sensitivity of HF-fed Control and EC-FoxO1 KD mice was assessed by intraperitoneal insulin tolerance test after 14 weeks of HF diet and 4 hr fasting. (**H**) Area over the curve (AOC, Control n = 14, EC-FoxO1 KD n = 16). (**I**) Plasma glucose levels of HF-fed Control (n = 14) and EC-FoxO1 KD (n = 16) mice after 4 hr fasting. (**J--K**) eWAT gene expression analysis by qPCR (Control n = 6--7, EC-FoxO1 KD n = 6). Data in all panels are expressed as mean ± SEM; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, calculated with two-tailed unpaired *t*-test (**F, I, J, K**) or post hoc Bonferroni-corrected *t*-tests when a statistical significance was detected by two-way ANOVA model (**A,C,D**).](elife-39780-fig6){#fig6}

EC drive the changes in glucose metabolism {#s2-5}
------------------------------------------

EC rely dominantly on glycolysis to support angiogenesis ([@bib8]) and a previous study reported that FoxO1 overexpression represses EC metabolism ([@bib43]). Therefore, we hypothesized that the changes in glucose utilization were due, at least in part, to increased metabolic activity of EC resulting from EC-FoxO1 depletion. To explore this possibility, we isolated the EC fraction from white adipose tissue depots of mice fed a HF diet for 7 weeks and first assessed gene expression of main glycolytic pathway genes. Consistent with the findings observed with whole adipose tissue, increased mRNA levels of glycolytic genes *Slc2a1*, *Pfkm* and *Pfkfb3* were detected in the EC fraction from adipose tissue of HF-fed EC-FoxO1 KD mice ([Figure 7A--B](#fig7){ref-type="fig"}). We also tested whether the elevated gene expression of glycolytic markers in EC from EC-FoxO1 KD mice would correspond with greater glycolytic capacity, as assessed by cellular glucose uptake and changes in glucose consumption and the accumulation of lactate. In agreement with higher transcript levels of *Slc2a1*, EC freshly isolated from adipose tissue of HF-fed EC-FoxO1 KD mice displayed increased glucose uptake than EC from floxed controls ([Figure 7C](#fig7){ref-type="fig"}). Moreover, rates of glucose consumption and lactate production were higher in EC with FoxO1 depletion compared to control cells ([Figure 7D--E](#fig7){ref-type="fig"}). Additionally, we observed elevated *Mki67* mRNA in the EC fraction from EC-FoxO1 KD mice, indicating that an enhanced proliferative state coincides with the glycolytic activity of these EC ([Figure 7F](#fig7){ref-type="fig"}).

![FoxO1 is a critical regulator of glucose metabolism in EC.\
(**A, B, F**) Gene expression analysis of EC fraction from adipose tissue from Control (n = 3--6) and EC-FoxO1 KD (n = 4--5) mice fed a HF diet for 7 weeks. (**C--E**) Increased glucose uptake (**C**) glucose consumption (**D**) and lactate production (**E**) in EC fraction from HF-fed EC-FoxO1 KD (n = 4) mice compared to Control (n = 4--5). Data in all panels are expressed as mean ± SEM; \*p \< 0.05, \*\*p \< 0.01, calculated with two-tailed unpaired *t*-test (**A,B,C,F**) or post hoc Bonferroni-corrected *t*-tests when a statistical significance was detected by two-way ANOVA model (**D,E**).](elife-39780-fig7){#fig7}

To corroborate that dysregulation of FoxO1 signaling is directly involved in disruption of glycolytic processes, we cultured skeletal muscle EC in low (5 mmol/L) and high glucose (25 mmol/L) conditions, as previous in vitro studies have shown that hyperglycemia can both increase FoxO1 activity ([@bib39]) and stall EC metabolism ([@bib10]; [@bib44]; [@bib11]). As expected, high-glucose significantly increased FoxO1 protein levels in cultured EC ([Figure 8A--B](#fig8){ref-type="fig"}) and provoked changes in established FoxO1 target genes *Cdkn1b* (p27) and *Ccnd1* (cyclin D1) ([Figure 8---figure supplement 1A--B](#fig8s1){ref-type="fig"}) that are involved in cell proliferation. Consistent with increased FoxO1 levels and activity, high-glucose conditions also lowered the mRNA levels of glycolytic pathway components *Slc2a1, Hk2*, and *Pfkfb3* ([Figure 8C--E](#fig8){ref-type="fig"}). Importantly, pharmacological inhibition of FoxO1 significantly reversed the high-glucose-induced reduction of each of these genes ([Figure 8C--E](#fig8){ref-type="fig"}), which correlated with elevated protein levels of HK2 and PFKFB3 ([Figure 8F--I](#fig8){ref-type="fig"}). Accordingly, treatment with FoxO1 inhibitor AS1842856 increased cellular glucose uptake and consumption in microvascular ECs, which corresponded with higher extracellular lactate levels ([Figure 8J--L](#fig8){ref-type="fig"}). Collectively, these findings indicate that lower FoxO1 levels and activity increase glycolytic and proliferative activities of EC. This induces a profound increase in glucose consumption by these cells, which consequently leads to higher glucose utilization at the tissue level, ultimately impacting whole-body glucose homeostasis.

![Pharmacological inhibition of FoxO1 in SMEC reproduces in vitro the endothelial phenotype observed with EC-*Foxo1* depletion.\
(**A--B**) Representative Western blot images (**A**) and quantitative analysis (**B**) of FoxO1 and β-actin levels in primary EC from skeletal muscle cultivated under low (5 mmol/L) or high (25 mmol/L) glucose conditions for 48 hr (n = 5). Results are expressed relative to β-actin levels. (**C--E**) Transcript analysis by qPCR of microvascular EC from skeletal muscle cultivated under low (5 mmol/L, n = 8) or high (25 mmol/L, n = 8) glucose conditions for 48 hr in the presence or absence of the FoxO1 inhibitor (1 μmol/L AS1842856, n = 7) in the last 18 hr. (**F--I**) Representative Western blot images and quantitative analysis of hexokinase II (HK2, (**F,G**), PFKFB3 (**H, I**) and β-actin levels in primary EC from skeletal muscle cultivated under high glucose (25 mmol/L) conditions and treated with 1 μmol/L AS1842856 for 24 hr (n = 6). Results are expressed relative to β-actin levels. (**J**) Glucose uptake after 18 hr treatment with 1 μmol/L AS1842856 of microvascular EC from skeletal muscle cultivated under high glucose conditions (n = 3). (**K--L**) Glucose consumption (**K**) and Lactate production (**L**) were assessed in SMEC in the absence or presence of 1 μmol/L AS1842856. Cells were pretreated with 1 μmol/L AS1842856 for 24 hr (n = 4). Data in all panels are expressed as mean ± SEM; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, calculated with two-tailed unpaired *t*-test (**B,J**), post hoc Bonferroni-corrected *t*-tests when a statistical significance was detected by two-way ANOVA model (**C--E, K--L**) or two-tailed paired *t*-test (**G,I**).](elife-39780-fig8){#fig8}

EC-FoxO1 depletion is sufficient to alter EC response to HF diet {#s2-6}
----------------------------------------------------------------

FoxO1 and FoxO3 can demonstrate overlapping functions in EC ([@bib27]) and previous studies reported that double depletion of *Foxo1* and *Foxo3* can either demonstrate similar effects as FoxO1 deficiency or have significant additive effects ([@bib45]; [@bib15]). This led us to investigate whether double depletion of endothelial *Foxo1* and *Foxo3* would result in a greater angiogenic response in HF-fed mice. HF-fed EC-FoxO1,3 KD mice (generated using the tamoxifen-inducible, endothelial-specific Cre driver: *Pdgfb*-CreERT2) presented lower levels of fasting glucose ([Figure 9A--C](#fig9){ref-type="fig"}) and reduced adiposity, as evidenced by lighter subcutaneous and rWAT depots, compared to their littermate controls ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Similar to what was observed in EC-FoxO1 KD mice on a HF diet, increased expression of *Pecam1* was detected in eWAT and skeletal muscle of HF-fed EC-FoxO1,3 KD mice ([Figure 9D](#fig9){ref-type="fig"}), indicating greater EC content in these tissues. Additionally, increased expression of glycolytic markers was observed in eWAT and EC fraction from adipose tissue of HF-fed EC-FoxO1,3 KD mice ([Figure 9E--F](#fig9){ref-type="fig"}). Consistent with these findings, increased glucose uptake ([Figure 9G](#fig9){ref-type="fig"}) and lactate production ([Figure 9H](#fig9){ref-type="fig"}) were also detected in the EC fraction from HF-fed EC-FoxO1,3 KD mice. Notably, these measurements demonstrated that combined depletion of EC-*Foxo1* and *Foxo3* elicits a similar, but not additive effect, when compared to EC-*Foxo1* alone, indicating that FoxO1 is the dominant regulator of the EC response to HF diet.

![EC-*Foxo1,3* depletion increases vascular growth and upregulates endothelial glycolytic processes comparable to EC-*Foxo1* depletion.\
(**A**) PCR of genomic DNA from eWAT of Control (*Foxo1,3^f/f^*) and EC-FoxO1,3 KD mice using primers for the floxed and deleted alleles for each gene. (**B**) *Foxo1* and *Foxo3* mRNA levels in microvascular EC from white adipose tissue (Control n = 4, EC-FoxO1,3 KD n = 3). (**C**) Glucose levels after 14 weeks of HF feeding and 4 hr fasting (Control n = 6, EC-FoxO1,3 KD n = 6). (**D**) Endothelial cell marker *Pecam1* mRNA level in skeletal muscle and eWAT of HF-fed Control and EC-FoxO1,3 KD mice (Control n = 5, EC-FoxO1,3 KD n = 5). (**E--F**) Gene expression analysis by qPCR of eWAT (**E**) and EC fraction from adipose tissue (**F**) of HF-fed Control (n = 3--5) and EC-FoxO1,3 KD (n = 3--5) mice. (**G--H**) Increased glucose uptake (**G**) and lactate production (**H**) in EC fraction from adipose tissue of EC-FoxO1,3 KD mice (n = 4) compared to Control counterparts (n = 4--5). Data in all panels are expressed as mean ± SEM; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, calculated with two-tailed unpaired *t*-test.](elife-39780-fig9){#fig9}

Discussion {#s3}
==========

Herein, we provide evidence that endothelial FoxO1 is critical to the development of metabolic disorders in obesity through the converging actions of controlling metabolic activity and angiogenic fate of the endothelium. Our data underscore that the manipulation of endothelial FoxO1 levels profoundly modifies the endothelial phenotype under an obesogenic diet, with lower levels of EC-FoxO1 evoking increased endothelial metabolism and capillary growth, most robustly detected within visceral adipose. These effects were sufficient not only to prevent the detrimental obesity-driven alterations in visceral adipose tissue but also to elicit increased glucose clearance leading to higher glucose tolerance in HF-fed mice ([Figure 10](#fig10){ref-type="fig"}). Broadly, these findings provide support for the emerging concept that intrinsic metabolic properties of EC actively influence whole-body energy balance.

![Schematic depicting the influence of FoxO1 in controlling the response of ECs to a HF diet.\
In wild-type mice, FoxO1 represses glycolysis, which prevents endothelial cell growth. This results in impaired angiogenesis during adipose tissue expansion as well as dysfunction of the adipose tissue, which consequently leads to decreased glucose tolerance and increased serum and intra-tissue levels of triglycerides. Conversely, when FoxO1 is depleted in endothelial cells, up-regulation of glycolytic genes accelerates glycolysis, which supports increased cellular metabolism, growth and proliferation. This, in turn, increases the nutrient demand of endothelial cells, resulting in higher uptake and consumption of glucose and an increased production of lactate. The accelerated endothelial cell growth ultimately preserves adipose tissue functions and promotes improved systemic glucose tolerance and lipid metabolism.](elife-39780-fig10){#fig10}

A marked increase in vascular density in the adipose tissue was the bona fide phenotypic consequence of EC-FoxO1 depletion, which was strikingly evident under the stress of obesity-related tissue expansion. This demonstrates that endothelial FoxO1 is a prime regulator of adipose tissue microvascular remodeling in adult mice, underlining our hypothesis that FoxO1 levels are directly implicated in limiting the angiogenic response of ECs in obesity. Despite the enlargement of capillaries that was observed in EC-FoxO1 KD mice, these mice displayed a healthier adipose phenotype that lacked the metabolic dysfunctions typically caused by obesity. This finding is in line with previous evidence suggesting that enhanced EC-FoxO1 activity is associated with reduced adipocyte insulin sensitivity in the adipose tissue of obese individuals ([@bib19]). Therefore, our findings indicate not only that EC-FoxO1 depletion beneficially increases adipose vascular density but also emphasize the intimate interplay of EC and adipocytes and the crucial role of angiogenesis in the maintenance of adipose tissue functions ([@bib6]; [@bib7]).

In contrast, EC-FoxO1 depletion induced relatively modest expansion of skeletal muscle vasculature. Our findings suggest that the tissue-restricted pattern of FoxO1-driven vascular growth is highly dependent on the co-presence of angiogenic factors within the local environment, which is impacted by nutritional status. Besides the higher levels of angiogenic mediators detected in adipose tissue of EC-FoxO1 KD mice, another argument favoring this hypothesis is provided by our observation that EC-FoxO1 depletion was associated with increased EC content within skeletal muscle only under HF feeding. It is noteworthy that previous reports showed that HF-feeding increases VEGF-A protein within the skeletal muscle ([@bib36]; [@bib25]) and FoxO1 levels within skeletal muscle capillaries ([@bib25]). In this context, our findings also support the concept that the impaired vascular growth reported with sustained HF diet results from the repressive action of EC-FoxO1 ([@bib22]; [@bib29]) rather than the lack of a pro-angiogenic stimulus.

Interestingly, EC from HF-fed EC-FoxO1 KD mice demonstrated markedly enhanced glycolytic activity, based on the increased expression of glycolytic markers and concomitant increase in glucose uptake, glucose consumption and lactate production. Although the regulation of endothelial metabolism by *Foxo1* overexpression was reported in cultured EC ([@bib43]), our data provide novel evidence of the impact of lower FoxO1 levels on endothelial metabolism and its consequences to whole-body homeostasis. It has become recently clear that endothelial metabolic activation represents an important feature of excessive angiogenesis, and that its repression holds therapeutic promise particularly within the tumor microenvironment ([@bib31]; [@bib3]). Our study drives this concept from the opposite angle by highlighting the potential for induction of endothelial metabolic activity as an approach to overcome the impairments in adaptive capillary growth that prevail in obese individuals. In fact, our data strongly indicate that the metabolic endothelial adaptation seen in response to FoxO1 depletion results in beneficial expansion of microvascular EC content and prevents obesity-related disorders. The lack of additional influence of combined depletion of EC *Foxo1* and 3 with respect to expression of *Pecam1* and glycolytic pathway genes and glucose uptake reinforces FoxO1 as the dominant regulator of EC metabolic homeostasis. More importantly, these findings indicate FoxO1 as a central target for the manipulation of capillary EC response to obesity-induced conditions.

The finding that increased endothelial glycolysis induced by EC-FoxO1 depletion significantly impacts whole-body energy homeostasis is intriguing. Improvements in whole-body energy homeostasis subsequent to microvascular expansion have been observed previously ([@bib37]; [@bib25]; [@bib28]; [@bib1]). Nonetheless, these effects had been ascribed to the improved passive exchange of oxygen, nutrients, and hormones to parenchymal tissues due to the increased capillary EC surface area. Our findings add another dimension to the provocative idea that EC can actively impact metabolism at the tissue level by bringing to light the dynamic contribution of EC metabolic activity to whole-body energy homeostasis during obesity. Although currently available tools do not provide the resolution required for a quantitative in vivo assessment of glucose consumption specifically by microvascular EC, our data strongly suggest that increasing EC metabolic activity leads to increased glucose uptake from the circulation and thus positively influences systemic glucose usage and tolerance. In addition, several pieces of available knowledge provide support for our hypothesis. First, EC are uniquely positioned at the interface between the bloodstream and the tissue parenchymal cells, which provides them with preferential access to circulating metabolic substrates. Second, glucose uptake by these cells is mediated via glucose transporter 1 (GLUT1), an insulin-independent transporter that is widely recognized to regulate basal glucose disposal. Interestingly, a direct connection between endothelial GLUT1 level and whole-organ glucose metabolism under physiological conditions was reported in a mouse model of EC-*Hif1a* depletion ([@bib17]). Third, EC are among the most abundant cell types in the human body, accounting for 2--7% of the total cell number ([@bib2]; [@bib34]), with the majority of these EC residing within capillaries. Therefore, it is plausible that the combined increase in EC metabolic activity with the expansion of capillary EC number can impact the overall systemic glucose homeostasis. The exact contribution of EC metabolism to whole-body substrate utilization, however, merits further investigation, as EC-FoxO1 depletion reprogrammed both metabolic activity and angiogenic responses of EC.

Beyond the remarkable effect that we observed on whole-body glucose metabolism, our findings support the notion that the substantial increase in vascular growth resulting from EC-FoxO1 depletion also impacted lipid handling under HF feeding conditions. In fact, HF-fed EC-FoxO1 KD mice displayed lower adiposity and serum levels of triglycerides and glycerol and less lipid accumulation in the liver. Although this could constitute a direct consequence of vascular growth, as fatty acid oxidation is used to support de novo nucleotide synthesis in EC ([@bib32]), it is also likely to involve secondary compensatory effects triggered by sustained imbalances in global glucose homeostasis that result from increased EC metabolic activity.

A number of previous reports have shown that lower expression of EC-*Foxo1* leads to disrupted vascular remodeling ([@bib12]; [@bib35]; [@bib9]), which seemingly contradicts the phenotype we observed. A significant part of this discrepancy may arise from differences in experimental design and approach. Those studies used Cre-deleter models (Tie2-Cre and Cdh5-Cre) that broadly affect all vascular beds (including lymphatic endothelium) beginning at an early embryonic stage and also exhibit substantial Cre recombinase activity within hematopoietic lineages ([@bib4]; [@bib40]). In contrast, we employed a model of inducible EC-*Foxo1* depletion in adult mice, in which Cre activity was restricted to mature microvascular EC. Consistent with our findings, the induced depletion of EC-*Foxo1* in newborn mice resulted in increased EC growth and vessel enlargement within mouse retina ([@bib43]), although to a greater extent than the phenotype observed in our study. Interestingly, microvascular EC possess distinct tissue-specific molecular signatures ([@bib24]). In addition, it has been shown that EC-depletion of FoxO transcription factors can result in unique biological consequences in different tissue contexts ([@bib26]). Thus, it is likely that both the developmental stage and the tissue microenvironment contribute substantially to phenotype observed with EC-*Foxo1* depletion. These study-specific features emphasize that the methodological details need to be carefully considered in the interpretation of data from EC-*Foxo1* depletion and highlight that the impact of EC-depletion cannot necessarily be extrapolated to different tissue contexts.

Altogether, our study reveals that EC-FoxO1 depletion evokes increased glycolytic capacity of endothelial cells and enables microvascular expansion in conditions where an angiogenic stimulus is present, as exemplified by the capillary expansion seen in white adipose depots in HF-fed mice. The repercussions of these combined influences include profound improvements in white adipose tissue capacity to cope with the stimulus of sustained nutrient excess and systemic enhancement of glucose clearance. In conclusion, these effects clearly define FoxO1 as the major regulator of the EC response to HF diet through the repression of beneficial metabolic and angiogenic adaptations in response to the stimulus of nutrient excess. Finally, this study brings to light an unappreciated role of EC as a distinctive metabolic entity rather than a simple exchange interface and highlights the modulation of endothelial metabolic and angiogenic activity as a potential target in the treatment of obesity-related disturbances.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\               Designation                          Source or\                Identifiers                                             Additional\
  (species) or\                                                    reference                                                                         information
  resource                                                                                                                                           
  --------------------------- ------------------------------------ ------------------------- ------------------------------------------------------- ---------------------------------
  Strain,\                    *Foxo1^f/f^*\                        From the\                                                                         Generated by\
  strain background\          (FVB-*Foxo1^tm1Rdp^*)                laboratory of Dr\                                                                 crossing Foxo1,3,4f/f\
  (M. musculus,\                                                   Tara L. Haas                                                                      mice (FVB background;\
  FVB/n)                                                                                                                                             from the laboratory\
                                                                                                                                                     of Dr. Ronald A.\
                                                                                                                                                     DePinho)\
                                                                                                                                                     with FVB/n mice.

  Strain,\                    *Foxo1,3^f/f^*\                      From the laboratory\                                                              Generated by\
  strain background\          (FVB-*Foxo1^tm1Rdp^;*\               of Dr Tara L. Haas                                                                crossing Foxo1,3,4f/f\
  (M. musculus,\              *Foxo3^tm1Rdp^*)                                                                                                       mice (FVB background;\
  FVB/n)                                                                                                                                             from the laboratory of\
                                                                                                                                                     Dr. Ronald A. DePinho)\
                                                                                                                                                     with FVB/n mice.

  Strain,\                    Pdgfb-iCre\                          From the laboratory of\                                                           The founder mouse was\
  strain background\          \[B6-Tg(Pdgfb-icre\                  Dr. Marcus Fruttiger                                                              a kind gift from\
  (M. musculus,\              /ERT2)1Frut\]                                                                                                          Dr. Marcus Fruttiger..
  (C57BL/6 x CBA)F2)                                                                                                                                 

  Strain,\                    *Foxo1^iEC-D^*\                      This paper                                                                        Mice were generated\
  strain background\          \[FVB.B6-Tg\                                                                                                           by cross-breeding\
  (M. musculus,\              (Pdgfb-icre/ERT2)\                                                                                                     Pdgfb-iCre with\
  FVB.B6)                     1Frut; Foxo1^tm1Rdp^\]                                                                                                 *Foxo1^f/f^* mice,\
                                                                                                                                                     followed by\
                                                                                                                                                     backcrossing\
                                                                                                                                                     offspring with\
                                                                                                                                                     *Foxo1^f/f^* mice for\
                                                                                                                                                     3 + generations

  Strain,\                    *Foxo1,3^iEC-D^*\                    This paper                                                                        Mice were generated\
  strain background\          \[FVB.B6-Tg\                                                                                                           by cross-breeding\
  (M. musculus,\              (Pdgfb-icre/ERT2)\                                                                                                     Pdgfb-iCre with *Foxo1,3^f/f^*\
  FVB.B6)                     1Frut; Foxo1^tm1Rdp^;\                                                                                                 mice, followed\
                              Foxo3^tm1Rdp^\]                                                                                                        by backcrossing\
                                                                                                                                                     offspring with *Foxo1,3^f/f^*\
                                                                                                                                                     mice for\
                                                                                                                                                     3 + generations

  Cell line\                  Endothelial cell\                    This paper                                                                        Isolated freshly for\
  (primary\                   fraction from\                                                                                                         each experiment
  mouse adipose\              adipose tissue                                                                                                         
  derived\                                                                                                                                           
  endothelial cells,\                                                                                                                                
  male)                                                                                                                                              

  Cell line\                  Cultured\                            This paper                                                                        
  (primary\                   microvascular\                                                                                                         
  mouse skeletal\             EC, SMEC                                                                                                               
  muscle\                                                                                                                                            
  endothelial cells,\                                                                                                                                
  male)                                                                                                                                              

  Antibody                    Biotin Rat\                          BD Pharmingen             553371                                                  Cell purification
                              Anti-Mouse CD31                                                                                                        

  Antibody                    MitoProfile Total\                   Abcam                     ab110413                                                WB (1:500)
                              OXPHOS\                                                                                                                
                              Rodent WB\                                                                                                             
                              Antibody Cocktail                                                                                                      

  Antibody                    Mouse\                               Santa Cruz\               sc-47778                                                WB (1:5000)
                              Anti-β-actin                         Biotechnology                                                                     

  Antibody                    Peroxidase AffiniPure\               Jackson\                  115-035-003                                             WB (1:10,000)
                              Goat Anti-Mouse                      ImmunoResearch                                                                    

  Antibody                    Peroxidase AffiniPure\               Jackson\                  111-035-003                                             WB (1:10,000)
                              Goat Anti-Rabbit                     ImmunoResearch                                                                    

  Antibody                    Purified Rat Anti-Mouse\             BD Pharmingen             553141                                                  Cell purification
                              CD16/CD32\                                                                                                             
                              (Mouse BD Fc Block)                                                                                                    

  Antibody                    Purified Rat\                        BD Pharmingen             555289                                                  Cell purification
                              Anti-Mouse CD144                                                                                                       

  Antibody                    Rabbit\                              Cell Signaling            2148                                                    WB (1:1000)
                              Anti-α/β-tubulin                                                                                                       

  Antibody                    Rabbit\                              Cell Signaling            9272                                                    WB (1:1000)
                              Anti-Akt                                                                                                               

  Antibody                    Rabbit\                              Cell Signaling            4107                                                    WB (1:1000)
                              Anti-HSL                                                                                                               

  Antibody                    Rabbit\                              Cell Signaling            2867T                                                   WB (1:1000)
                              Anti-Hexokinase                                                                                                        

  Antibody                    Rabbit\                              Cell Signaling            13123S                                                  WB (1:1000)
                              Anti-PFKFB3                                                                                                            

  Antibody                    Rabbit\                              Cell Signaling            4058                                                    WB (1:1000)
                              Anti-phospho-Akt\                                                                                                      
                              (Ser473)                                                                                                               

  Antibody                    Rabbit\                              Cell Signaling            4139                                                    WB (1:1000)
                              Anti- phospho-HSL\                                                                                                     
                              (Ser563)                                                                                                               

  Sequence-\                  oFK1ckA:\                            ThermoFisher\             NA                                                      
  based\                      GCT TAG AGC\                         Scientific                                                                        
  reagent (oligonucleotide)   AGA GAT GTT\                                                                                                           
                              CTC ACA TT                                                                                                             

  Sequence-\                  oFK1ckB:\                            ThermoFisher\             NA                                                      
  based\                      CCA GAG TCT\                         Scientific                                                                        
  reagent (oligonucleotide)   TTG TAT CAG\                                                                                                           
                              GA AAT AA                                                                                                              

  Sequence-\                  oFK1ckC: CAA\                        ThermoFisher\             NA                                                      
  based\                      GTC\                                 Scientific                                                                        
  reagent (oligonucleotide)   CAT TAA TTC AGC\                                                                                                       
                              ACA TTG A                                                                                                              

  Sequence-\                  oFK2ckA: ATT CCT\                    ThermoFisher\             NA                                                      
  based\                      TTG GAA ATC\                         Scientific                                                                        
  reagent (oligonucleotide)   AAC AAA ACT                                                                                                            

  Sequence-based\             oFK2ckB: TGC TTT\                    ThermoFisher\             NA                                                      
  reagent (oligonucleotide)   GAT ACT ATT\                         Scientific                                                                        
                              CCA CAA ACCC                                                                                                           

  Sequence-\                  oFK1ckC: AGA TTT\                    ThermoFisher\             NA                                                      
  based\                      ATG TTC CCA CTT\                     Scientific                                                                        
  reagent (oligonucleotide)   GCT TCCT                                                                                                               

  Peptide,\                   Humalog\                             Lilly                     NA                                                      
  recombinant\                Insulin                                                                                                                
  protein                                                                                                                                            

  Commercial\                 PureLink\                            ThermoFisher Scientific   K182001                                                 
  assay or kit                Genomic DNA\                                                                                                           
                              Mini Kit                                                                                                               

  Commercial\                 EnzyFluo^TM^L-\                      BioAssay\                 EFLLC-100                                               
  assay or kit                lactate Assay Kit                    Systems                                                                           

  Commercial\                 Glycerol\                            Sigma-\                   MAK117                                                  
  assay or kit                Assay Kit                            Aldrich                                                                           

  Commercial\                 Glucose (HK)\                        Sigma-\                   GAHK20                                                  
  assay or kit                Assay                                Aldrich                                                                           

  Commercial\                 Lactate-Glo\                         Promega                   J5021                                                   
  assay or kit                Assay                                                                                                                  

  Commercial\                 RNeasy Mini Kit                      Qiagen                    74106                                                   
  assay or kit                                                                                                                                       

  Commercial\                 Triglyceride\                        Cayman\                   10010303                                                
  assay or kit                Colorimetric\                        Chemical\                                                                         
                              Assay kit                            Company                                                                           

  Chemical\                   AS1842856 FoxO1\                     EMD Millipore             344355                                                  
  compound,\                  inhibitor                                                                                                              
  drug                                                                                                                                               

  Chemical\                   Isoproterenol                        Tocris                    1747                                                    
  compound,\                                                                                                                                         
  drug                                                                                                                                               

  Chemical\                   Tamoxifen                            Sigma                     T5648                                                   
  compound, drug                                                                                                                                     

  Software,\                  Image J Analysis\                    National\                 <https://imagej.nih.gov/ij/download.html>               
  algorithm                   Software                             Institutes of\                                                                    
                                                                   Health                                                                            

  Software,\                  GraphPad Prism\                      GraphPad\                 <https://www.graphpad.com/scientific-software/prism/>   
  algorithm                   Version 6.07                         Software Inc.                                                                     

  Other                       11 kcal% fat w/\                     Research\                 D12329                                                  
                              sucrose Surwit Diet                  Diets                                                                             

  Other                       58 kcal% fat w/sucrose Surwit Diet   Research\                 D12331                                                  
                                                                   Diets                                                                             

  Other                       BODIPY\                              ThermoFisher\             D3922                                                   
                              493/503                              Scientific                                                                        

  Other                       Dynabeads                            ThermoFisher\             14311D                                                  
                                                                   Scientific                                                                        

  Other                       Fast TaqMan\                         ThermoFisher\             4444963                                                 
                              Master Mix                           Scientific                                                                        

  Other                       M-MLV reverse\                       New England\              M0253                                                   
                              transcriptase                        Biolabs                                                                           

  Other                       Streptavidin\                        BD IMag                   557812                                                  
                              Particles Plus -\                                                                                                      
                              DM                                                                                                                     

  Other                       Rhodamine\                           VectorLabs                RL1102                                                  
                              labeled *Griffonia*\                                                                                                   
                              (*Bandeiraea*)\                                                                                                        
                              *Simplicifolia* lectin                                                                                                 

  Other                       QIAzol Lysis\                        Qiagen                    79306                                                   
                              Reagent                                                                                                                

  Other                       SuperSignal\                         ThermoFisher\             34080                                                   
                              West Pico                            Scientific                                                                        

  Other                       Type I\                              ThermoFisher\             17100--017                                              
                              collagenase                          Scientific                                                                        

  Other                       Type II\                             ThermoFisher\             17101--005                                              \
                              collagenase                          Scientific                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

*Foxo1^f/f^* mice and *Foxo1,3^f/f^* mice were derived from outbreeding of *Foxo1,3,4^f/f^* mice ([@bib26]) with wild-type FVB/n mice, and genotyped to ensure homozygosity of the floxed allele(s). To permit the inducible endothelial-specific manipulation of *Foxo1* and *Foxo3a*, these mice were bred with *Pdgfb*-iCreERT2 mice (C57Bl/6 background) ([@bib5]). Offspring were back-crossed with *Foxo1^f/f^* or *Foxo1,3^f/f^* founders for a minimum of 3 generations prior to experimentation to establish genotypes Cre^-^;*Foxo1^f/f^* and Cre^+^;*Foxo1^f/f^* or Cre^-^;*Foxo1,3^f/f^* and Cre^+^;*Foxo1,3^f/f^*, respectively.

Animal studies {#s4-2}
--------------

We performed five separate animal studies using only male mice. To generate mice with postnatal endothelial cell-specific deletion of FoxO1 (EC-FoxO1 KD), or double deletion of *Foxo1* and *Foxo3* (EC-FoxO1,3 KD), Cre-mediated recombination was induced in 4--6 weeks old Cre^+^;*Foxo1^f/f^*; mice and Cre^+^;*Foxo1,3^f/f^*; mice by five consecutive *i.p.* injections of 200 µL tamoxifen (15 mg/mL in corn oil). Recombination of *Foxo1* (and *Foxo3)* alleles was confirmed via PCR analysis of genomic DNA ([@bib26]). In all experiments, EC-FoxO1 KD and EC-FoxO1,3 KD mice were compared with age-matched tamoxifen-injected Cre^-^;*Foxo1^f/f^* or Cre^-^;*Foxo1,3^f/f^* littermates (referred to as Control). No statistical method was used to predetermine the sample size. At 6--8 weeks of age, male mice within each litter were assigned randomly, according to their genotypes, to either normal chow (NC, 11% kcal from fat) or high-fat (HF, 58% kcal from fat, Surwit Diet) groups. Water and diet were provided *ad libitum*. Body weights and food intake of mice included in studies 1 and 2 were recorded weekly. Specific animal groups and the tests conducted were as followed: *Group 1:* Control and EC-FoxO1 KD mice received 16 week NC or HF diets (n = 6--7/group) and underwent body composition imaging at week 13, GTT and ITT (weeks 14, 15 respectively) and tissue collection at week 16 for whole tissue analyses (histology and RNA). Based on the apparent lack of influence of *Foxo1* deletion under NC diet in this group (see Results), subsequent testing focused on comparing the genotype differences observed in the HF condition: *Group 2:* Control and EC-FoxO1 KD mice (n = 7 and 8, respectively) underwent 14 week HF diet, metabolic testing (CLAMS) at week 13; ITT and tissue collection at week 14 for mitochondrial respiration, electron microscopy and serum analyses of TGs and glycerol. *Group 3 and 4*: Control and EC-FoxO1 KD mice (n = 5/group) and *Group 5:* Control and EC-FoxO1,3 KD (n = 6/group) underwent HF diet for 7, 5 and 14 weeks, respectively. Groups 3 and 5 were used to analyze 4 hr fasting glucose, and groups 3, 4 and 5 were used to isolate endothelial cell fractions from adipose depots for RNA and for glucose uptake, glucose consumption and lactate release assays. Animal studies were conducted in accordance with the American Physiological Society's guiding principles in the Care and Use of Animals, following protocols approved by the York University Committee on Animal Care.

Body composition analysis {#s4-3}
-------------------------

Body composition was examined by micro-computed tomography (Skyscan 1278; Bruker) using the step and shoot function, averaging four images/frame with a rotation step of 0.75 degrees. Mice were scanned at a voltage of 50kV, a current of 200 A with a 0.5 aluminum filter while anesthetized with isoflurane. Images were reconstructed using NRecon (local) and the entire trunk area fat mass was analyzed using CTAn.

Whole-body metabolism analysis {#s4-4}
------------------------------

Mice were monitored individually for oxygen consumption, carbon dioxide production, respiratory exchange ratio and locomotor activity using Indirect Calorimetry with the Columbus Comprehensive Lab Animal Monitoring System (CLAMS, Columbus Instruments, USA). Mice acclimated to CLAMS cages for 24 hr then data were recorded every 5 min for a 48 hr period. Mice had *ad libitum* access to food and water. VO~2~ and CO~2~ were normalized to body weight. Respiratory exchange ratio (RER) was calculated as the volume of CO~2~ relative to the volume of oxygen (VCO~2~/VO~2~).

Intra-peritoneal insulin and glucose tolerance tests (ITT and GTT) {#s4-5}
------------------------------------------------------------------

For ITT, Control and EC-FoxO1 KD mice were fasted for 4 hr and received an *i.p.* injection of insulin (0.75 U/kg BW). GTTs were conducted in overnight-fasted control and EC-FoxO1 KD mice using an *i.p.* injection of glucose (1.75 g/kg BW). Blood glucose was measured by glucometer (Freestyle Lite, Abbott Diabetes Care, ON, Canada) at post-injection time-points 0, 20, 40 and 60 min (ITT) or 0, 30, 60, 90 and 120 min (GTT).

In vivo insulin stimulation {#s4-6}
---------------------------

Insulin stimulation of skeletal muscle was conducted as described previously ([@bib25]) and the phosphorylation state of Akt was assessed by Western blotting.

Ex vivo adipose explant incubation {#s4-7}
----------------------------------

Epididymal fat pads were cut into \~ 80 mg pieces and pre-incubated with low glucose DMEM containing 1% fatty acid-free BSA for 30 min (37°C) before 30 min incubation with insulin (25 mU/mL) or isoproterenol (10 µmol/L). Tissue explants were snap frozen in liquid nitrogen and the phosphorylation states of Akt or HSL were assessed by Western blotting.

Mitochondrial respiration {#s4-8}
-------------------------

Respirometry studies in freshly extracted epididymal white adipose tissue (eWAT) were performed using high-resolution respirometry (Oroboros Oxygraph-2k, Oroboros Instruments, Crop, Innsbruck, Austria). EWAT fat pads were prepared as done previously ([@bib21]), minced in MIR05 buffer, weighed and immediately placed in separate Oroboros Oxygraph-2k in respiration media (MIR05) containing 20 mmol/L creatine ([@bib30]). State three respiration was stimulated with the addition of ADP \[5 mmol/L\] in the presence of pyruvate \[5 mmol/L\] and malate \[4 mmol/L\] followed by glutamate \[10 mmol/L\] and succinate \[20 mmol/L\]. Respiration experiments were completed at 37°C before the oxygraph chamber reached 150 mmol/L \[O~2~\]. Mitochondrial membrane integrity was tested with the addition of 10 mmol/L cytochrome c oxidase at the end of each protocol.

Western Blot {#s4-9}
------------

Total protein extraction from isolated cells or tissues was performed as previously described ([@bib22]). Primary antibodies were as follows: FoxO1, Ser473-pAkt, Akt, Ser563-pHSL, HSL, HK2, PFKFB3, α/β-tubulin, β-actin and Mitoprofile Total OXPHOS Cocktail. Secondary antibodies were goat anti-rabbit or anti-mouse IgG-horseradish peroxidase. Membranes were developed using enhanced chemiluminescence and densitometry analysis was performed with ImageJ Analysis Software (NIH).

Imaging of adipose tissue {#s4-10}
-------------------------

For microvascular quantification, pieces of eWAT were fixed in 4% formaldehyde and stained with BODIPY 493/503 (0.25 µg/mL) and rhodamine-*Griffonia Simplicifolia* lectin (1:100) to visualize adipocytes and microvessels, respectively. Images were taken with a Zeiss LSM700 confocal microscope (10x or 20x objectives) using identical gain settings for all samples. Microvascular content and branchpoint numbers were quantified from 3 to 4 10x fields of view per animal, and vessel diameters from 20x images, using Image J Analysis Software (NIH). For morphometric analysis of adipocytes, eWAT was fixed in 4% formaldehyde. Paraffin embedding, sectioning and hematoxylin and eosin staining were carried out by The Centre for Phenogenomics (Toronto, Canada). Adipocyte area was analyzed in three randomly selected fields of view (4x objective) using ImageJ Analysis Software (NIH). For quantification of capillaries, de-paraffinized sections were stained with fluorescein isothiocyanate-conjugated *Griffonia Simplicifolia* Lectin-1 (1:100) and Rhodamine Wheat Germ Agglutinin (1:200). Images were acquired using a 10X objective on a Zeiss inverted microscope equipped with a digital cooled CCD camera, capturing 3--4 independent fields of view per mouse. Image J software was used to quantify the numbers of capillaries and adipocytes in corresponding *Griffonia* and Wheat Germ Agluttinin-stained images, respectively.

Muscle histology and Electron Microscopy (EM) {#s4-11}
---------------------------------------------

Cross-sections of EDL were stained with *Griffonia simplificolia-*FITC for assessment of capillary to fiber ratio ([@bib25]). Pieces of EDL muscles from HF-fed Control and EC-FoxO1 KD mice (n = 4/group) were fixed in 2% glutaraldehyde and 4% paraformaldehyde in 0.1M phosphate buffer (pH = 7.4) and sent for EM processing at the Hospital for Sick Children (Toronto, Canada). Cross-sectional images of capillaries (identified by lack of smooth muscle cell coverage) were captured by a blinded EM technician. Luminal diameters and endothelial cross-sectional areas of all detected capillaries within each sample were assessed using Image J software.

Measurement of lipids and lactate {#s4-12}
---------------------------------

Serum triglycerides and glycerol levels were measured using commercial kits. Triglycerides were also measured in homogenates of liver and gastrocnemius muscle. Lactate levels were assessed in serum from HF-fed Control and EC-FoxO1 KD mice and in phenol-free cell culture medium of adipose-derived endothelial cells and SMEC also using a commercial kit.

Endothelial cell isolation and culture {#s4-13}
--------------------------------------

SMEC were isolated from collagenase digested skeletal muscle using rat anti-mouse VE-cadherin antibody-coated Dynabeads and biotinylated rat anti-mouse CD31 antibody-coated streptavidin-coupled beads, cultivated as described previously ([@bib29]), and used in experiments between passages 4 and 7. For glucose and FoxO1 inhibitor treatments, cells were plated and after overnight attachment, culture medium was replaced by low (5 mmol/L) or high-glucose (25 mmol/L) DMEM 10% FBS and incubated for 48 hr and 1 µmol/L AS1842856 was added to the medium 18 hr prior to testing. To examine the influence of FoxO1 inhibition on protein levels of glycolytic enzymes, SMEC were plated sparsely. After overnight attachment, culture medium (high-glucose DMEM with 10% FBS) was replaced by high-glucose DMEM with 0.1% FBS and the cells were stimulated with 1 µmol/L AS1842856 for 24 hr before lysis in RIPA buffer for protein extraction. For the isolation of adipose-derived endothelial cells, white adipose depots were pooled and digested with 0.5% Type I collagenase for 20 min at (37°C) with shaking. Centrifugation (300x*g* for 5 min) was used to separate adipocytes from the stromal vascular fraction (SVF). The re-suspended SVF was passed through a 100 μm-cell strainer, then pre-incubated with rat anti-mouse CD16/CD32 coupled to Dynabeads to deplete immune cells. Endothelial cells were selected using rat anti-mouse VE-cadherin antibody-coated Dynabeads and biotinylated rat anti-mouse CD31 antibody-coated streptavidin-coupled beads. Cells were plated on gelatin-coated plates and maintained in high-glucose DMEM (10% FBS) until utilization the following day.

Metabolic assays {#s4-14}
----------------

Glucose uptake was assessed in freshly adipose-derived endothelial cells and in SMEC using Glucose Uptake-Glo Assay following manufacturer's instructions. To examine the effects of *Foxo1* depletion on the glycolytic capacity of endothelial cells, freshly isolated adipose-derived endothelial cells were incubated with high-glucose DMEM plus 10% dialyzed FBS for 32 hr. The effects of FoxO1 inhibition were examined in SMEC pre-treated with 1 µmol/L AS1842856 for 24 hr in high-glucose DMEM plus 0.1% FBS following incubation with high-glucose DMEM plus 10% dialyzed FBS for 32 hr. Glucose consumption and lactate production were determined in cell culture medium at different time points (0, 8 and 24 hr) using commercial kits.

Gene expression analysis {#s4-15}
------------------------

Total RNA was isolated from liver, skeletal muscle (plantaris), adipose tissue (BAT, eWAT and subcutaneous), adipose-derived endothelial cell and CD16/CD32 fractions and SMEC using RNeasy Mini Kit (Qiagen Inc.), reverse-transcribed and analyzed by real-time PCR on the Rotor-Gene Q platform (Qiagen Inc.) using Fast TaqMan Master Mix and TaqMan primer sets (listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Each target gene was calculated relative to *Hprt1* or *Actb* levels and expressed as 2^-ΔCt^.

Data reporting and statistical analyses {#s4-16}
---------------------------------------

All data reported are for independent biological replicates; each mouse being considered as one biological replicate. Averaged values were used when technical replicates (analysis of the same sample in duplicates) were performed. For in vitro assays, experiments were repeated at least three times and a sample size of ≥ 3 biological replicates was used. Samples or data points were excluded only in the case of a technical equipment or human error that caused a sample to be poorly controlled. Statistical analyses were performed using Prism 5 (GraphPad Software Inc.). Significance was established at p \< 0.05, by unpaired Student's *t-*test or 2-way ANOVA with Bonferroni post hoc tests, as appropriate. Data are shown as means ± SEM and *P* values are indicated in each Figure as \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.
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Reviewing Editor
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Endothelial-specific *Foxo1* depletion prevents obesity-related disorders by increasing vascular metabolism and growth\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mark McCarthy as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript by Rudnicki and colleagues studies the impact of endothelial cell (EC)-specific depletion of FoxO1 on high-fat diet induced obesity. By utilizing a tamoxifen-inducible EC-specific *Foxo1* knock-out mouse model, the authors demonstrate that upon high-fat diet, EC *Foxo1* elimination results in greater vascular growth in visceral white adipose tissue and healthier adipose tissue expansion, resulting in improved glucose intolerance. The authors suggested that the mechanism for metabolic improvements is increased endothelial glycolytic capacity and enhanced endothelial proliferation. Overall, the present work provides novel insights into the role of endothelial FoxO1 on controlling vascular growth under diet induced obese conditions, particularly in adipose tissues.

Essential revisions:

A number of important issues would need to be clarified prior to additional review:

1\) A major concern is that the authors have neglected or misinterpreted several important previous papers on FoxO1 depletion and endothelial cell function, including:

a\) Furuyama T, et al., 2004, have shown that *Foxo1*-null mice are embryonic lethal at E11 due to impaired vasculogenesis;

b\) The paper by Dharaneeswaran H, et al., 2014 demonstrated that EC-specific disruption of *Foxo1* reproduced the phenotypes of *Foxo1*-null mice;

c\) Matsukawa M, et al. (Genes to Cells, 2009) also suggested that *Foxo1*-null endothelial cells showed an abnormal morphological response to VEGF-A and TGF-β, implicating an impairment in angiogenesis upon *Foxo1* depletion;

d\) Even in the paper reported by Tanaka J, et al., 2009, which has been cited in the current manuscript, showed that EC-specific *Foxo1* knock-out mice displayed no gross or metabolic abnormalities;

e\) The work done by Wilhelm K, et al., 2016, utilized the exact same mouse model as the authors have employed (*Pdgfb*-creERT2/*Foxo1* flox/flox) to demonstrate that EC loss of *Foxo1* caused hyperplastic vasculature but resulted in the inability of ECs to extend proper sprouts and uncoordinated vascular growth.

Considering many of these previously published articles are not supporting the findings in the present manuscript, the authors should carefully evaluate their own results and extensively discuss possible reasons for the inconsistency.

2\) More functional evidence other than merely gene expression data is required to support the conclusion that EC depletion of *Foxo1* promotes endothelial glycolytic capacity, such as utilizing measurements of glycolytic rates on a Seahorse.

3\) The authors state that EC-*Foxo1* depletion stimulates vascular growth during age-related adipose expansion (Figure 1) but no data are shown concerning the age-related adipose expansion (for example increased visceral adipose tissue mass normalized to body weight from week 0 to week 16 for each genetic background) and depletion of *foxo1* is shown only at mRNA level.

Similarly, all data are originated from direct comparison between two different genetic backgrounds (floxed mice are derived from outbreeding of *Foxo1*, 3, 4ff mice with wild-type FVB/n mice, described to be resistant to high fat diet-induced obesity, and the genetic background of *Pdgfb*-creERT2 mice is not indicated) under high fat diet. Comparisons between diets (normal chow and high fat) in the same genetic backgrounds (including body weights, fat depot and muscle weights as well as metabolic parameters) will be more relevant.

4\) The lower adipocyte size described in Figure 4 may explain the greater microvascular content in Figure 2. The microvascular content must be expressed as capillary:adipocyte ratio as performed for muscle (Figure 3).

10.7554/eLife.39780.024

Author response

> Essential revisions:
>
> A number of important issues would need to be clarified prior to additional review:
>
> 1\) A major concern is that the authors have neglected or misinterpreted several important previous papers on FoxO1 depletion and endothelial cell function, including:
>
> a\) Furuyama T, et al., 2004, have shown that Foxo1-null mice are embryonic lethal at E11 due to impaired vasculogenesis;
>
> b\) The paper by Dharaneeswaran H, et al., 2014 demonstrated that EC-specific disruption of Foxo1 reproduced the phenotypes of Foxo1-null mice;
>
> c\) Matsukawa M, et al. (Genes to Cells, 2009) also suggested that Foxo1-null endothelial cells showed an abnormal morphological response to VEGF-A and TGF-β, implicating an impairment in angiogenesis upon Foxo1 depletion;
>
> d\) Even in the paper reported by Tanaka J, et al., 2009, which has been cited in the current manuscript, showed that EC-specific Foxo1 knock-out mice displayed no gross or metabolic abnormalities;
>
> e\) The work done by Wilhelm K, et al., 2016, utilized the exact same mouse model as the authors have employed (Pdgfb-creERT2/Foxo1 flox/flox) to demonstrate that EC loss of Foxo1 caused hyperplastic vasculature but resulted in the inability of ECs to extend proper sprouts and uncoordinated vascular growth.
>
> Considering many of these previously published articles are not supporting the findings in the present manuscript, the authors should carefully evaluate their own results and extensively discuss possible reasons for the inconsistency.

We respectfully disagree with the statement that we have misinterpreted several important previous papers on *Foxo1* depletion and endothelial cell function. We initially did not discuss findings from these papers for the sake of focus and brevity. However, we agree with the reviewers that the manuscript will benefit from added discussion of these points, which is included in the revised version of our manuscript. Importantly, we highlight a unifying emergent theme -- that the influence of endothelial FoxO1 varies with context \[developmental stage; tissue type; vessel type; presence of environmental stressors\], and that these variations are unmasked through the use of a variety of experimental models and methodological approaches. We elaborate on this below.

Stage of development at the time of FoxO1 deletion in endothelial cells (EC) significantly influences outcomes:Whilst embryonic deletion of EC-*Foxo1* (or global FoxO1) leads to lethality with apparent disruption of vascular organization (not EC differentiation),^1-3^ post-natal conditional deletion of EC-FoxO1 is not lethal.^4^ These contrasting phenotypes (lethal vs. not lethal) observed with the genetic manipulation of FoxO1 in EC reflect the disparate incidence of angiogenesis in pre- vs. postnatal life and are also consistent with differences in the process of embryonic/developmental angiogenesis compared to angiogenesis within adult tissues. Throughout embryogenesis, the entire organism undergoes active expansion, and all vasculature (macro and micro) likewise is stimulated to expand, remodel and specialize according to location in the vascular tree. In turn, at the adult stage, angiogenesis occurs only when stimulated, and only within selective locations of the vasculature. Since endothelial cells (EC) are considered to be quiescent in the adult, angiogenic growth is orchestrated by a selected subset of mature EC, which do not exhibit the functional plasticity observed in embryonic EC. Moreover, recent data suggest that capillary formation and expansion in the adult occurs by clonal expansion of mature endothelial cells^5^ whereas random integration or cell mixing mediates developmental angiogenesis. All these differences ultimately impact how the vasculature expands at different stages. Importantly, the effects on cell morphology and sprouting and the poor responsiveness to VEGF and TGFβ in response to FoxO1 deletion reported by Furuyama et al.^1^ and Matsukawa et al.^6^ were observed with the use of embryonic stem cells, which exhibit some but not all characteristics of mature differentiated endothelial cells. These data were challenged by findings published by Paik et al.,^7^ who demonstrated that the deletion of FoxO transcription factors in EC of adult mice can either increase their proliferative capacity enhancing the response to VEGF or show no detectable phenotypic alteration. Thus, while findings reported with embryonic stem cells provide some clue of the effects of FoxO1 in EC, caution should be applied in extrapolating these results to the phenotype of mature EC. Furthermore, the differential processes involved in neovascularization within embryonic and adult vasculature offer a plausible rationale for the distinct phenotypes observed with FoxO1 deletion and limit the extent of direct comparison that can be made between the two types of experimental models.

The tissue microenvironment is crucial in establishing the consequence of EC-FoxO1 deletion: It has been reported that organ-specific differences remarkably affect phenotypic features of EC when depletion of EC-FoxO transcription factors is induced in adult mice,^7^ which is consistent with the current knowledge that microvascular EC show distinct molecular signatures within different tissues according to unique extravascular and intrinsic signals.^8^ Thus, the microenvironment exerts substantial control over angiogenesis,^9^ and tissues exhibit a range of angiogenic capacities at the adult stage. For example, in the absence of an added metabolic stimulus, skeletal muscle microvasculature in adult mice is very stable and angiogenic signals are minimal. Conversely, adipose tissue undergoes expansion through-out maturity as adipose depot size increases with age, and it produces a multitude of pro-angiogenic factors that help to coordinate capillary growth with tissue expansion. In this context and in agreement with the previous cited study,^7^ data from our current paper (and prior study,^10^ despite use of a different FoxO deletion strategy) provide strong evidence that these tissue environments affect the outcome of EC--*Foxo1* deletion. Indeed, while EC-*Foxo1* deletion exerted minimal phenotypic effects within skeletal muscle of normal chow-fed mice, increased vascular density was detectable in white adipose tissue of the same mice. In considering the study of Wilhelm et al.,^4^ it is apparent that we observed some similar and some disparate phenotypic features of EC with *Foxo1* depletion. Of note, although the authors had used a similar inducible deletion model, they induced the deletion of *Foxo1* in newborn mice and assessed the effects of endothelial-specific depletion of *Foxo1* specifically in retinal *developmental* angiogenesis. Consistent with their findings, we also observed more vessels and larger vessels in the adipose tissue vasculature when the deletion of *Foxo1* was induced in adult male mice. However, the more extensive disorganization of the vasculature observed by Wilhelm et al. but not in our study may be interpreted as the consequence of stronger stimulation of the EC by the potently pro-angiogenic environment within the maturing retina. Considering that those investigators closely tracked angiogenic processes within a narrow time window (i.e. 14-21 days) while we reported end-point vascular differences after 16 weeks of diet intervention, we cannot rule out the occurrence of alterations in endothelial cell sprouting/migration in our model. Our study was not designed to have the temporal resolution to assess those events, but it would be valuable to address this question in future investigations.

Differences between Cre deleter models used to elicit FoxO1 depletion: Importantly, the selection of Cre mouse model can lead to divergent phenotypes directly affecting the outcomes of EC-*Foxo1* depletion. Tie2-Cre and Cdh5-cre models used in Dharaneeswaran et al.^3^ and Tanaka et al.^11^ studies are widely employed to manipulate gene expression within the endothelium. However, both models show substantial Cre recombinase activity within hematopoietic lineages,^12-14^ which can confound the analysis and interpretation of the resultant phenotype. In addition, as both promoters are active in all endothelial cell populations, these constitutively active endothelial Cre transgenic models, affect all vascular beds, including lymphatic vasculature^15,\ 16^ beginning at an early embryonic stage being thus generally referred to as endothelial-specific knockout models. It is worth noting that in direct contradiction with previous studies,^1,\ 2^ Tanaka et al^11^ reported no lethality with embryonic EC-*Foxo1* deletion and as the reviewers also highlighted their EC-specific *Foxo1* knockout mice "were born at term in Mendelian ratios and showed no gross or metabolic abnormalities." Strikingly, additional studies^2,\ 3^ that also used the Tie2-cre deleter to target Foxo1 reported embryonic lethality at approximately E11.0. The discrepancies between these studies and the Tanaka et al. study can probably be attributed to the variable cre activity associated with this Cre model. Indeed, Heffner et al. demonstrated that "embryos from the same litter display very different levels of Cre excision, ranging from endothelial-specific to nearly ubiquitous in non-target tissues."^14^ In contrast with these previous studies, we did not use a constitutively active endothelial Cre transgenic model. Instead, the endothelial Cre/ERT2 model used in our study induces Cre recombinase activity at the adult stage (by nature of the timing of the tamoxifen-injection) under the control of the Platelet-derived growth factor B (*Pdgfb*) promoter.^17^*Pdgfb* expression is observed in capillary endothelial cells and in the endothelium of growing arteries during embryonic development and is restricted to capillaries into the adult stages.^18^ Therefore, the activation of *Pdgfb*-driven Cre recombinase activity at the adult stage favours the influence of genetic manipulation within capillaries not affecting all EC equally. As a consequence, the divergent pattern of Cre activity between our model and the Tie2 or Cadh5-deleter models^3,\ 11^ also could contribute to the differences in phenotype observed by us compared to those studies.

Overall, through these examples, we hope to have made a case that a) we do have a strong awareness of preceding studies and how their results relate to our own investigation and b) differences in the methodological approaches/experimental models need to be carefully considered in the interpretation of data from EC-*Foxo1* depletion when comparing the findings of these previously published articles and our data. Finally, we also would like to emphasize that ours is the first report documenting the effect of EC-*Foxo1* depletion in adult male mice, uniquely assessing angiogenesis of adipose tissue and skeletal muscle in the context of obesity. Overall, our study brings to light several novel concepts in vascular remodeling of these tissues in a pathophysiological context, which is relevant for understanding disease processes in the adult. While our answer to the reviewers has been extensive to justify our position, we have inserted a much briefer mention of these issues into the Discussion of the manuscript (seventh paragraph), as we share the reviewers' point of view that it is beneficial to readers for us to explain differences in models.

> 2\) More functional evidence other than merely gene expression data is required to support the conclusion that EC depletion of Foxo1 promotes endothelial glycolytic capacity, such as utilizing measurements of glycolytic rates on a Seahorse.

We have now added to the revised manuscript a new set of data to illustrate that EC-*Foxo1* depletion, as well as the inhibition of FoxO1 transcriptional activity, leads to increased glycolytic capacity of endothelial cells. For this experiment, we isolated microvascular endothelial cells from adipose tissue of adult male mice with EC-*Foxo1* depletion (EC-FoxO1 KD) fed a high-fat diet (HF) for 5 weeks. Due to the limited yield of cells obtained, we were not able to assess the glycolytic capacity of those cells measuring the extracellular acidification rate of cell medium by Seahorse analysis as suggested by the reviewers. As a surrogate approach to provide a functional read-out, we conducted matched measurements of glucose consumption and lactate production over time by measuring the lowering of glucose and the accumulation of lactate in the media over a 32 hour time window. In line with the data we provided before on fluorescent glucose uptake and lactate release, endothelial cells freshly isolated from adipose tissue of high fat-fed EC-FoxO1 KDmice displayed higher rates of glucose consumption than cells from floxed littermate controls. These findings were paralleled with increased lactate levels in the cell culture medium. These data argue in favor of increased glycolysis, the predominant bioenergetic pathway for ECs.^19^ To complement these observations, we repeated the measurement of lactate levels of microvascular endothelial cells from skeletal muscle cultivated in high-glucose conditions treated with FoxO1 inhibitor (AS1842856) with several protocol modifications. In the originally submitted manuscript, lactate levels were measured in cell medium after endothelial cells were incubated with FoxO1 inhibitor for only 18 hours in high-glucose medium containing 10% FBS. This time, we pre-incubated the cells for 24 hours with FoxO1 inhibitor in high-glucose medium with 0.1% FBS for 24 hours. After this 24h-pretreatment, culture medium was replaced by high-glucose DMEM plus 10% dialyzed FBS and cells were incubated in the presence and absence of FoxO1 inhibitor for 32 hours and cell media was collected in different time points (0, 8, 24 and 32 hours) for the assessment of glucose and lactate levels. Consistent with the findings in endothelial cells with EC-FoxO1 KD, we detected increased rates of glucose consumption and lactate productions when FoxO1 transcriptional activity was inhibited. Finally, we analyzed cultured microvascular EC treated with FoxO1 inhibitor for 24 hours for protein levels of hexokinase 2 and PFKFB3, and observed an increase in protein that matched with their elevated gene expression. We have added these new data to the revised manuscript (Figure 7D-E, Figure 8F-I, and Figure 8K-L).

> 3\) The authors state that EC-Foxo1 depletion stimulates vascular growth during age-related adipose expansion (Figure 1) but no data are shown concerning the age-related adipose expansion (for example increased visceral adipose tissue mass normalized to body weight from week 0 to week 16 for each genetic background) and depletion of foxo1 is shown only at mRNA level.
>
> Similarly, all data are originated from direct comparison between two different genetic backgrounds (floxed mice are derived from outbreeding of Foxo1, 3, 4ff mice with wild-type FVB/n mice, described to be resistant to high fat diet-induced obesity, and the genetic background of Pdgfb-creERT2 mice is not indicated) under high fat diet. Comparisons between diets (normal chow and high fat) in the same genetic backgrounds (including body weights, fat depot and muscle weights as well as metabolic parameters) will be more relevant.

With respect to age-related adipose expansion: We thank for the reviewers for this observation. Because we did not conduct analyses of adipose depots at week 0 of the diet, we realize that we cannot directly comment on age-related adipose expansion. We have adjusted the wording in the Results and Discussion accordingly.

With respect to FoxO1 depletion: We have added Western blots of capillaries segments freshly isolated from skeletal muscle of EC-FoxO1 KD mice and Control littermates to provide further evidence of the efficacy of FoxO1 deletion at the protein level. Protein level decreased by \~ 70%, indicating that the decrease in FoxO1 mRNA is representative of a loss of FoxO1 protein (Figure 1D).

With respect to mouse background: We realize that our description of the mouse strains was not sufficiently detailed, leading to misinterpretation. *Foxo1^fl/fl^*mice are on an FVB background. The *Pdgfb*-iCreERT2 founder is on a C57BL/6 background. After cross-breeding these two mouse strains, subsequent generations were bred back to the *Foxo1^fl/fl^* strain to obtain homozygosity for the floxed alleles. Litters were back-crossed to the *Foxo1^fl/fl^* founder line for 3 generations prior to beginning experiments. It also is important to note that all experiments were conducted on littermates, sharing the identical genetic background. Littermate mice homozygous for the floxed *Foxo1* or *Foxo1,3* alleles but not expressing Cre recombinase were used as controls in our study. In our revised manuscript we have better described these details about the mice used in our study both in the Results and the Materials and methods section.

> 4\) The lower adipocyte size described in Figure 4 may explain the greater microvascular content in Figure 2. The microvascular content must be expressed as capillary:adipocyte ratio as performed for muscle (Figure 3).

We understand the reviewers' concern and agree that the adipocyte size could confound the assessment of microvascular density within adipose tissue. To address this question, we have quantified capillary number in paraffinized sections of eWAT from HF-fed Control and EC-FoxO1 KDmice (same experimental group used in the whole-mount staining analyses). The obtained data further confirm our previous findings of increased vascular density in adipose tissue of HF-fed EC-FoxO1 KD mice and clearly showed that the phenotype described in the originally submitted manuscript is not secondary to smaller adipocyte size. These data have been included in the revised manuscript (Figure 3F-G).
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